Overtreatment of low-grade prostate cancer (Gleason score ≤ 6) is a recognized problem today, with systematic prostate gland sampling triggered by prostate-specific antigen (PSA) measurements.1 The extent to which overtreatment is caused by fear of death resulting from cancer, fear of litigation from undertreatment, and misaligned incentives that reimburse more for treating rather than monitoring when appropriate is not known. Nevertheless, fear of death resulting from cancer likely plays some role, and removing the label “cancer” could reduce unnecessary treatment of low-grade disease.2,3 On the other hand, undertreatment of prostate cancer and a missed opportunity for cure in those who could benefit is a real risk of relabeling a cancer as noncancer. We have decided on an alternative modification of the Gleason scoring system and herein present the arguments for and against removing the label of cancer from Gleason 6 tumors. We believe that our alternative approach may help: one, ensure that patients receive the proper counseling/treatment; two, reduce the risk of overtreatment and its associated harms; and three, improve shared decision making.

Rationale for Removing the Label of Cancer From Gleason 6 Tumors
The updated Gleason grading system is misleading for patients and physicians.

The Gleason grading system, based on five architectural patterns of a tumor, has evolved over time.4 For practical purposes, Gleason patterns (grade) 1 and 2, or scores 2 to 4 noted in the classic system, are not diagnosed on needle biopsies because of poor correlation with radical prostatectomy grade and poor reproducibility among expert pathologists.5 The Gleason system has been modified based on a 2005 consensus conference,4 whereby lesions previously referred to as Gleason scores 2 to 4 in the classic system are now assigned a higher grade (Gleason score 6) in the modified system; however, those previously graded as Gleason score 6 in the classic system are often graded as Gleason score 7 tumors in the modified system. Although this modification of grading could improve the prognosis of some men who have cancer-specific outcomes intermediate between the modified Gleason score 6 and the classical Gleason score 3 + 4 cancers,6 the larger effect of the 2005 modification has been to improve the perceived cancer-specific survival by 26% through the Will Rogers phenomenon.7

Best evidence using robust end points from various sources, including competing risk analyses, surgical series, nonrandomized cohort studies, and randomized trials, has demonstrated the similarity of outcomes for men with Gleason score 6 tumors treated or not in the PSA era.812 Taken together, these data demonstrate that using a time horizon of 10 to 15 years, less than 3% of men diagnosed with Gleason score ≤ 6 and classified as low risk (based on a PSA < 10 ng/mL and stage ≤ T2a) will die as a result of prostate cancer whether treated or not. The evidence calls into question the need for treating men with Gleason score 6 tumors (graded in the modified system) who have a life expectancy of fewer than 10 to 15 years, especially if considered low risk.13 But the reality is that today, men older than age 65 years with Gleason score 6 tumors on needle biopsy are treated as though they harbor a tumor with the same biologic potential as those with a Gleason score ≥ 714,15—a one-size-fits-all approach that is inconsistent with medical evidence suggesting that physicians and patients view a Gleason score 6 cancer today as a lethal phenotype in most cases.

Fear induces overtreatment of prostate cancer.

In the National Cancer Institute Patterns of Care Study16 and recent updates from the CAPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry,14,17 approximately half of newly diagnosed men have Gleason score ≤ 6 at diagnosis, and 80% to 90% depending on age undergo some form of treatment even when age at diagnosis is > 75 years. Raldow et al18 recently reported that among men age 67 to 84 years with cancers labeled as low grade in the WHO classification scheme, one in three with an estimated life expectancy of < 5 years and 50% to 60% with an estimated life expectancy of 5 to 10 years underwent curative treatment with radiation or surgery. This clearly represents a large disconnect between evidence and practice. Although there may be multiple reasons for overtreatment of prostate cancer, fear of dying as a result of cancer surely plays a role in decisions to proceed with treatment among men with Gleason 6 tumors. Because patients generally interpret the assignment of Gleason score 6 as an intermediate cancer on a scale of 2 to 10, it is easy to see why most patients believe they harbor a lethal disease that needs immediate treatment.

Rationale for Leaving the Label of Cancer Attached to Gleason Score 6 Tumors
Morphologically and genetically, Gleason score 6 is cancer with the ability to invade tissues.

Gleason score 6 cancer is composed of Gleason pattern 3 cancer, which shares cytologic and molecular alterations associated with higher Gleason patterns and has the ability to extend locally beyond the prostate and invade nerves. Gleason pattern 3 cancer harbors many of the molecular alterations associated with higher-grade cancers, including loss of the basal cell layer, overexpression of alpha-methylacyl-CoA racemase, glutathione S-transferase hypermethylation and downregulation, and TMPRSS2ERG gene fusions.19 The overlap in molecular alterations between Gleason pattern 3 and higher Gleason patterns suggests that the designation of cancer is appropriate.

Biopsy Gleason score underestimates disease grade and extent.

On the basis of the intermediate end points of pathologic grade and stage, biopsy Gleason score underestimates both grade and extent of disease. Among men at a median age of 58 years who had at least a 10-core prostate biopsy, 36% of Gleason score 5 to 6 tumors were upgraded at radical prostatectomy if tertiary patterns were considered, and 25% were if tertiary patterns were not considered.20 The rate of upgrading was 35% for Gleason scores 5 to 6 on biopsy to Gleason score ≥ 7 at radical prostatectomy when studies that had evaluated at least 100 patient cases since 1992 were included.20

In addition to upgrading, men who are thought to harbor Gleason score ≤ 6 on biopsy may have more extensive non–organ-confined disease. In a study evaluating men who met different criteria for enrollment in active surveillance, 70% to 80%, depending on inclusion criteria, were organ confined and Gleason score 6 on pathologic review of radical prostatectomy specimens.21 Furthermore, among men chosen for active surveillance based on a Gleason score ≤ 6 and treated surgically after a median of 1.3 years after enrollment, 80% had organ-confined disease.22 Thus, one could argue that if one in three to one in five men thought to harbor Gleason score ≤ 6 tumors actually have high-grade or non–organ-confined disease, assigning a noncancer moniker to these low-grade cancers would disadvantage a substantial proportion of men by delaying curative therapy.

The risk of upgrading from a biopsy Gleason score 6 to higher grade within the prostate correlates with multiple factors, including serum PSA levels, clinical stage, and extent of cancer on biopsy,20 and the risk of harm from the cancer depends on age and the presence or absence of comorbidities. Although one could devise complicated rules for which Gleason score 6 tumors on biopsy should be called carcinomas and which ones should not, this would introduce an unreasonable level of complexity, not even factoring in that the definitions would change over time as new knowledge and techniques were acquired.

Renaming Gleason score 6 tumors as noncancer could result in a missed opportunity for cure.

Because biopsy Gleason score underestimates both grade and disease extent, and because grade and disease extent are predictive of cancer-specific survival,11,23 the identification of a Gleason score 6 cancer on biopsy is important information that could lead to earlier management, with an improved cancer-specific outcome, for two reasons. First, a biopsy Gleason score 6 tumor may reflect the presence of a higher grade or more extensive disease that was not sampled. If Gleason 6 on biopsy were not labeled as cancer, the potential for higher-grade or more extensive disease might be ignored, and physician recommendations (or compliance with recommendations) for immediate treatment or careful monitoring when appropriate might not occur. Second, a Gleason score 6 tumor on biopsy seems in a small percent of patients to progress to higher-grade carcinoma; although the rate of this progression is unknown, it presumably increases with time.24 If labeled as a benign lesion, progression of Gleason score 6 cancer could be missed, resulting in treatment administered at an incurable stage.

Renaming Gleason score 6 tumors as noncancer would result in medical liability.

Undoubtedly, renaming Gleason score 6 tumors as benign lesions would risk medical liability for pathologists and urologists.25 Pathologists could be liable for underdiagnosing cancer, leading to a delay in diagnosis. Currently, medical liability is virtually unheard of for a pathologist who undergrades a carcinoma. Although the issue is one of semantics, the change in diagnosis from noncancer to cancer would seem to be more significant than one of grade change in a carcinoma, especially to a lay jury. Similarly, some urologists would be liable if they did not treat a tumor that was later discovered to be incurable.

Modification of the Gleason Scoring System Retaining the Word Cancer and Emphasizing the Indolent Behavior of Gleason 6 Tumors

There is a precedent for retaining the term carcinoma for tumors that are indolent. For example, squamous cell carcinoma of the skin is a common tumor that like low-grade prostate carcinoma is morphologically carcinoma yet has a negligible risk of mortality. Patients are reassured about the typically benign clinical course of this tumor and consequently not overly concerned when diagnosed with carcinoma, accepting conservative treatment. Rather than avoid the term carcinoma, patients and physicians need to be educated about the indolent behavior of Gleason score 6 tumors and alternatives to immediate treatment.

In the absence of definitive markers of the lethal phenotype, a new paradigm is needed to express the risk associated with Gleason score 6 tumors. We propose to adopt at Johns Hopkins an alternative approach based on a modified Gleason scoring system referred to as prognostic grade group. Five prognostic categories will be reported based on prostate biopsy (Table 1). For men undergoing radical prostatectomy from 2004 to 2011, these prognostic grade groups from 1 to 5 have been associated with 5-year biochemical recurrence-free survivals of 94.6%, 82.7%, 65.1%, 63.1%, and 34.5%, respectively (Pierorazio et al, manuscript in preparation). These data are consistent with the literature supporting the concepts that on prostate biopsy: one, current Gleason score 6 tumors are more homogeneous and associated with better prognosis than in the past7,26 because of reclassification of what was previously referred to as Gleason score 6 to Gleason score 7 today; two, as compared with Gleason score 3 + 4, Gleason score 4 + 3 is associated with a greater disease extent and higher rate of biochemical failure after curative intervention2729; and three, when compared with Gleason score 8 tumors, Gleason scores of 9 and 10 are associated with lower rates of freedom from disease after curative intervention.30 However, we acknowledge that 5-year biochemical recurrence-free survival is only an intermediate end point, and longer follow-up is necessary to determine if these prognostic groupings will be associated with more robust clinically meaningful end points.


Table 1. Gleason Score Prognostic Grade Groups

Table 1. Gleason Score Prognostic Grade Groups

Gleason Score Prognostic Grade Group
≤ 6* I/V*
3 + 4 = 7 II/V
4 + 3 = 7 III/V
8 IV/V
9-10 V/V

*A man's risk of death as a result of prostate cancer is similar whether treated or not over 10 to 15 years after diagnosis if associated with low clinical stage (T1c to T2a) and prostate-specific antigen < 10 ng/mL.1

We believe that this system retains the proven prognostic value of the Gleason system4 and allows continued comparison with older literature, while emphasizing for patients and physicians that Gleason score 6 should be considered in the context of a prognostic category of 1 of 5, not 6 of 10. In addition, the reporting emphasizes that based on the conclusions of a recent National Institutes of Health Consensus Conference,1 those men with low-risk disease (Gleason score 6, PSA < 10 ng/mL, and clinical stage T1c to T2a) who are untreated have a similar cancer-specific survival when compared with those treated over 10 to 15 years after diagnosis. It is hoped that this will alleviate some of the fear associated with a diagnosis of Gleason score 6 “cancer” and give patients a more realistic perspective regarding their prognosis whether treated or not.

© 2012 by American Society of Clinical Oncology

The author(s) indicated no potential conflicts of interest.

Provision of study materials or patients: Alan W. Partin

Manuscript writing: All authors

Final approval of manuscript: All authors

1. PA Ganz, JM Barry, W Burke, etal: National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer Ann Intern Med 156: 591595,2012 Crossref, MedlineGoogle Scholar
2. JC Nickel, M Speakman: Should we really consider Gleason 6 prostate cancer? BJU Int 109: 645,2012 Crossref, MedlineGoogle Scholar
3. BA Chabner, M Smith: Call it cancer Oncologist 17: 149150,2012 Crossref, MedlineGoogle Scholar
4. JI Epstein, WC Allsbrook Jr, MB Amin, etal: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29: 12281242,2005 Crossref, MedlineGoogle Scholar
5. JI Epstein: Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made Am J Surg Pathol 24: 477478,2000 Crossref, MedlineGoogle Scholar
6. F Dong, C Wang, AB Farris, etal: Impact on the clinical outcome of prostate cancer by the 2005 International Society of Urological Pathology modified Gleason grading system Am J Surg Pathol 36: 838843,2012 Crossref, MedlineGoogle Scholar
7. PC Albertsen, JA Hanley, GH Barrows, etal: Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97: 12481253,2005 Crossref, MedlineGoogle Scholar
8. C Parker, D Muston, J Melia, etal: A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival Br J Cancer 94: 13611368,2006 Crossref, MedlineGoogle Scholar
9. P Stattin, E Holmberg, JE Johansson, etal: Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study J Natl Cancer Inst 102: 950958,2010 Crossref, MedlineGoogle Scholar
10. WV Shappley 3rd, SA Kenfield, JL Kasperzyk, etal: Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort J Clin Oncol 27: 49804985,2009 LinkGoogle Scholar
11. SE Eggener, PT Scardino, PC Walsh, etal: Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185: 869875,2011 Crossref, MedlineGoogle Scholar
12. TJ Wilt, MK Brawer, MJ Barry, etal: The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT)—Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer Contemp Clin Trials 30: 8187,2009 MedlineGoogle Scholar
1. JL Mohler: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer J Natl Compr Canc Netw 8: 145,2010 Crossref, MedlineGoogle Scholar
14. MR Cooperberg, JM Broering, PR Carroll: Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28: 11171123,2010 LinkGoogle Scholar
15. BL Jacobs, Y Zhang, TA Skolarus, etal: Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse Health Aff (Millwood) 31: 750759,2012 Crossref, MedlineGoogle Scholar
16. AS Hamilton, PC Albertsen, TK Johnson, etal: Trends in the treatment of localized prostate cancer using supplemented cancer registry data BJU Int 107: 576584,2011 Crossref, MedlineGoogle Scholar
17. MR Cooperberg, JM Broering, PW Kantoff, etal: Contemporary trends in low risk prostate cancer: Risk assessment and treatment J Urol 178: S14S19,2007 Crossref, MedlineGoogle Scholar
18. AC Raldow, CJ Presley, JB Yu, etal: The relationship between clinical benefit and receipt of curative therapy for prostate cancer Arch Intern Med 172: 362363,2012 Crossref, MedlineGoogle Scholar
19. GJ Netto, L Cheng: Emerging critical role of molecular testing in diagnostic genitourinary pathology Arch Pathol Lab Med 136: 372390,2012 Crossref, MedlineGoogle Scholar
20. JI Epstein, Z Feng, BJ Trock, etal: Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61: 10191024,2012 Crossref, MedlineGoogle Scholar
21. V Iremashvili, L Pelaez, M Manoharan, etal: Pathologic prostate cancer characteristics in patients eligible for active surveillance: A head-to-head comparison of contemporary protocols Eur Urol 62: 462468,2012 Crossref, MedlineGoogle Scholar
22. M Bul, X Zhu, A Rannikko, etal: Radical prostatectomy for low-risk prostate cancer following initial active surveillance: Results from a prospective observational study Eur Urol 62: 195200,2012 Crossref, MedlineGoogle Scholar
23. A Bill-Axelson, L Holmberg, M Ruutu, etal: Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364: 17081717,2011 Crossref, MedlineGoogle Scholar
24. TB Sheridan, HB Carter, W Wang, etal: Change in prostate cancer grade over time in men followed expectantly for stage T1c disease J Urol 179: 901904,2008 Crossref, MedlineGoogle Scholar
25. IB Dunn, D Kirk: Legal pitfalls in the diagnosis of prostate cancer BJU Int 86: 304307,2000 Crossref, MedlineGoogle Scholar
26. H Miyamoto, DJ Hernandez, JI Epstein: A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy Hum Pathol 40: 16931698,2009 Crossref, MedlineGoogle Scholar
27. MJ Burdick, CA Reddy, J Ulchaker, etal: Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer Int J Radiat Oncol Biol Phys 73: 14391445,2009 Crossref, MedlineGoogle Scholar
28. DE Kang, NJ Fitzsimons, JC Presti Jr, etal: Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: Results from the SEARCH database Urology 70: 277282,2007 Crossref, MedlineGoogle Scholar
29. DV Makarov, H Sanderson, AW Partin, etal: Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 167: 24402442,2002 Crossref, MedlineGoogle Scholar
30. A Sabolch, FY Feng, S Daignault-Newton, etal: Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation Int J Radiat Oncol Biol Phys 81: e351e360,2011 Crossref, MedlineGoogle Scholar


Supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Opinions expressed in this article should not be interpreted as official positions of the National Cancer Institute, National Institutes of Health, or US Department of Health and Human Services.


No companion articles


DOI: 10.1200/JCO.2012.44.0586 Journal of Clinical Oncology 30, no. 35 (December 10, 2012) 4294-4296.

Published online October 01, 2012.

PMID: 23032616

ASCO Career Center